Opioids and immunosupression in oncological postoperative patients

Summary Introduction: Recent animal studies demonstrated immunosuppressive effects of opioid withdrawal resulting in a higher risk of infection. The aim of this study was to determine the impact of remifentanil discontinuation on Post-Anesthesia Care Unit (PACU)-acquired infection after a schedule of sedoanalgesia of at least 6 days. Method: All patients over 18 years of age with a unit admission of more than 4 days were consecutively selected. The study population was the one affected by surgical pathology of any origin where sedation was based on any hypnotic and the opioid remifentanil was used as analgesic for at least 96 hours in continuous perfusion. Patients who died during admission to the unit and those with combined analgesia (peripheral or neuroaxial blocks) were excluded. Bivariate analysis was performed to determine risk factors for infection acquired in the unit. A comparative study between periods of 6 days before and after the cessation of remifentanil was performed. Paired samples test and McNemar test was used for quantitative and categorical variables, respectively. Results: There were 1,789 patients admitted to the PACU during the study and the population eligible was constituted for 102 patients. The incidence rate of PACU-acquired infection was 38 per 1,000 PACU days. Ventilator-associated pneumonia was the most frequently diagnosed PACU-acquired infection. Pseudomona aeruginosa was the most frequently isolated microorganism. Hospital mortality was 36.27%. No statistically significant differences were seen in the incidence of HAI in cancer patients in relation to discontinuation of remifentanil (p=0.068). Conclusion: The baseline state of immunosuppression of cancer patients does not imply a higher incidence of HAI in relation to the interruption of remifentanil. It would be of interest to carry out a multicenter PACU study that included immunological patterns.

Saved in:
Bibliographic Details
Main Authors: Bonilla-García,José Luis, Cortiñas-Sáenz,Manuel, Pozo-Gavilán,Esperanza del
Format: Digital revista
Language:English
Published: Associação Médica Brasileira 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302017000900753
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0104-42302017000900753
record_format ojs
spelling oai:scielo:S0104-423020170009007532018-02-22Opioids and immunosupression in oncological postoperative patientsBonilla-García,José LuisCortiñas-Sáenz,ManuelPozo-Gavilán,Esperanza del remifentanil morphine opioid healthcare-associated infections unit-acquired infection withdrawal immunosuppression critical care mortality Summary Introduction: Recent animal studies demonstrated immunosuppressive effects of opioid withdrawal resulting in a higher risk of infection. The aim of this study was to determine the impact of remifentanil discontinuation on Post-Anesthesia Care Unit (PACU)-acquired infection after a schedule of sedoanalgesia of at least 6 days. Method: All patients over 18 years of age with a unit admission of more than 4 days were consecutively selected. The study population was the one affected by surgical pathology of any origin where sedation was based on any hypnotic and the opioid remifentanil was used as analgesic for at least 96 hours in continuous perfusion. Patients who died during admission to the unit and those with combined analgesia (peripheral or neuroaxial blocks) were excluded. Bivariate analysis was performed to determine risk factors for infection acquired in the unit. A comparative study between periods of 6 days before and after the cessation of remifentanil was performed. Paired samples test and McNemar test was used for quantitative and categorical variables, respectively. Results: There were 1,789 patients admitted to the PACU during the study and the population eligible was constituted for 102 patients. The incidence rate of PACU-acquired infection was 38 per 1,000 PACU days. Ventilator-associated pneumonia was the most frequently diagnosed PACU-acquired infection. Pseudomona aeruginosa was the most frequently isolated microorganism. Hospital mortality was 36.27%. No statistically significant differences were seen in the incidence of HAI in cancer patients in relation to discontinuation of remifentanil (p=0.068). Conclusion: The baseline state of immunosuppression of cancer patients does not imply a higher incidence of HAI in relation to the interruption of remifentanil. It would be of interest to carry out a multicenter PACU study that included immunological patterns.info:eu-repo/semantics/openAccessAssociação Médica BrasileiraRevista da Associação Médica Brasileira v.63 n.9 20172017-19-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302017000900753en10.1590/1806-9282.63.09.753
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Bonilla-García,José Luis
Cortiñas-Sáenz,Manuel
Pozo-Gavilán,Esperanza del
spellingShingle Bonilla-García,José Luis
Cortiñas-Sáenz,Manuel
Pozo-Gavilán,Esperanza del
Opioids and immunosupression in oncological postoperative patients
author_facet Bonilla-García,José Luis
Cortiñas-Sáenz,Manuel
Pozo-Gavilán,Esperanza del
author_sort Bonilla-García,José Luis
title Opioids and immunosupression in oncological postoperative patients
title_short Opioids and immunosupression in oncological postoperative patients
title_full Opioids and immunosupression in oncological postoperative patients
title_fullStr Opioids and immunosupression in oncological postoperative patients
title_full_unstemmed Opioids and immunosupression in oncological postoperative patients
title_sort opioids and immunosupression in oncological postoperative patients
description Summary Introduction: Recent animal studies demonstrated immunosuppressive effects of opioid withdrawal resulting in a higher risk of infection. The aim of this study was to determine the impact of remifentanil discontinuation on Post-Anesthesia Care Unit (PACU)-acquired infection after a schedule of sedoanalgesia of at least 6 days. Method: All patients over 18 years of age with a unit admission of more than 4 days were consecutively selected. The study population was the one affected by surgical pathology of any origin where sedation was based on any hypnotic and the opioid remifentanil was used as analgesic for at least 96 hours in continuous perfusion. Patients who died during admission to the unit and those with combined analgesia (peripheral or neuroaxial blocks) were excluded. Bivariate analysis was performed to determine risk factors for infection acquired in the unit. A comparative study between periods of 6 days before and after the cessation of remifentanil was performed. Paired samples test and McNemar test was used for quantitative and categorical variables, respectively. Results: There were 1,789 patients admitted to the PACU during the study and the population eligible was constituted for 102 patients. The incidence rate of PACU-acquired infection was 38 per 1,000 PACU days. Ventilator-associated pneumonia was the most frequently diagnosed PACU-acquired infection. Pseudomona aeruginosa was the most frequently isolated microorganism. Hospital mortality was 36.27%. No statistically significant differences were seen in the incidence of HAI in cancer patients in relation to discontinuation of remifentanil (p=0.068). Conclusion: The baseline state of immunosuppression of cancer patients does not imply a higher incidence of HAI in relation to the interruption of remifentanil. It would be of interest to carry out a multicenter PACU study that included immunological patterns.
publisher Associação Médica Brasileira
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302017000900753
work_keys_str_mv AT bonillagarciajoseluis opioidsandimmunosupressioninoncologicalpostoperativepatients
AT cortinassaenzmanuel opioidsandimmunosupressioninoncologicalpostoperativepatients
AT pozogavilanesperanzadel opioidsandimmunosupressioninoncologicalpostoperativepatients
_version_ 1756409975996940288